Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAJIC first-line CLL/SLL trial
2021-003936-10Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Apr 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing Acalabrutinib + venetoclax with Venetoclax + obinutuzumab (2 arms). Primary endpoint: Progression-free survival. Started Apr 2022; status: active.
02
Drugs
acalabrutinibvenetoclaxobinutuzumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2021-003936-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003936-10.